News 2019-03-29T16:54:21+00:00

Lantern Pharma announces multiple presentations at AACR 2019 highlighting advancements of its precision oncology pipeline of therapeutics using their AI-based platform, RADRTM, to identify gene signatures that predict potential response of patient’s tumor to a drug.

TiE Announces AI Driven Lantern Pharma as 2018 Top 50 Emerging Company. Lantern Pharma is excited to announce that it has been selected as a “2018 TiE50 winner” for the prestigious TiE50 Awards Program recognizing the world’s most innovative tech startups. This awards competition is part of TiE Inflect 2018, the world’s largest conference for tech entrepreneurs

TiE Inflect 2018 Announces Lantern Pharma as a 2018 TiE50 Finalist

Precision Oncology Company Lantern Pharma to Showcase Artificial Intelligence Approach

Lantern Pharma Joins Genomics England to Advance Their Precision Oncology Platform

Lantern Pharma: A Game Changing Precision Medicine Initiative

Lantern Pharma Raises $3.7 M in Series A Financing